Why the study?
Does rivaroxaban provide similar efficacy and safety to warfarin in chronic thromboembolic pulmonary hypertension patients undergoing pulmonary endarterectomy?
Does rivaroxaban provide similar efficacy and safety to warfarin in chronic thromboembolic pulmonary hypertension patients undergoing pulmonary endarterectomy?
Rivaroxaban may be a viable short-term alternative to warfarin for anticoagulation in CTEPH patients post-pulmonary endarterectomy.
Answers are grounded in this paper and cite their sources.
May support short-term rivaroxaban as warfarin alternative post-CTEPH endarterectomy; extends NOAC evidence to this surgical population.
Rivaroxaban may be as effective as warfarin in treating CTEPH patients after endarterectomy in the short term and can be used as an anticoagulant in these patients. However, studies with long-term follow-ups are needed to consolidate the strategy of treating these patients with rivaroxaban.
No takes yet. Share an insight, caveat, or question.
Barati et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: